COVID-19

J&J has now taken its COVID-19 vaccine into Phase 3 trials for both a 1-dose and 2-dose regimen. Pic:getty/JHDTstockimages

J&J launches Phase 3 trial for 2-dose COVID-19 vaccine

By Rachel Arthur

Johnson & Johnson has launched a second global Phase 3 trial for its Janssen COVID-19 vaccine candidate: this time exploring a 2-dose regimen (its existing Phase 3 trial is for a 1-dose regimen).

Follow us

Products

View more

Webinars